Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (7915)	12/2/1998 3:42:00 PM
From: aknahow	Respond to of 17367

Bob, 2 for 3. December '98 Special Meeting of XOMA Shareholders to Vote on Change of Domicile 29, 7:30 am, XOMA Headquarters, 2910 7th St., Berkeley, CA February '98 1998 Year End Financial Results week of 15-19 March '99 American Chemical Society 21-25, Anaheim, CA Marc Better, PhD, Session Chair: Recent Developments in Expression Systems Pat Gavit, XOMA Scientist, "Isolation of Anti-fungal Peptides from Escherichia coli after Simultaneous in situ Lysis and Peptide Cleavage"

To: Robert K. who wrote (7915)	12/2/1998 3:50:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bob, 3 for 4. Factsheet Updated. November 1998 Index Company Description Financial Data NEUPREX® NEUPREX® Clinical Program R & D Management Product Pipeline NEUPREX® Phase III Clinical Trial Update: Meningococcemia: > 285 patients enrolled UK and US Hemorrhage/trauma: > 460 patients in 40 trauma centers